MALDI-TOF MS has previously been applied to chronic myeloid leukemia (Knights et al. 2006) to identify processed and presented epitopes eluted from MHC which led to the identification of a novel peptide from PRTN3, which was detected among the more abundant MHC-ligands. Here, HLA-C is linked to chronic myelogenous leukemia, BCR-ABL1 positive.